Category: Media Release

Race Oncology 2022 AGM Presentation by CEO Phil Lynch and CSO Dr Daniel Tillett.

Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is a highly targeted precision oncology agent…

Race Oncology June 2022 Quarterly Investor Briefing

Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session.